Late-phase inflammation: Influence on morbidity

Journal of Allergy and Clinical Immunology

Volumn 98, Issue 6 SUPPL. 2, 1996, Pages

  Charlesworth, Ernest N ^a  

^a Brenham Clinic   (United States)

Author keywords

Antihistamines; Asthma; Cetirizine; Corticosteroids; Late phase response; Misoprostol; Terfenadine

Indexed keywords

CETIRIZINE; CHLORPHENIRAMINE; CORTICOSTEROID; PROMETHAZINE;

ALLERGIC DISEASE; ASTHMA; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INFLAMMATORY INFILTRATE; PRIORITY JOURNAL; PROVOCATION; REVIEW; TREATMENT PLANNING;

ASTHMA; HUMANS; IMMUNOTHERAPY; INFLAMMATION; INFLAMMATION MEDIATORS; MORBIDITY; RESPIRATORY MECHANICS; TIME FACTORS;

EID: 0030464802     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0091-6749(96)80114-x     Document Type: Article

References (59)

1. National Center for Health Statistics: National Health Interview Survey. Hyattsville (MD): United States Department of Health and Human Services, Public Heatlth Service, Centers for Disease Control, 1980-1987.
2. Evans R III, Mullally DI, Wilson RW, Gerger PJ, Rosenberg HM, Grauman JS. et al. National trends in the morbidity and mortality of asthma in the US: prevalence, hospitalization and death from asthma over two decades 1965-1984. Chest 1987;91:65S-74S.
3. Blackley CH. Experimental researches on the causes and nature of catarrhs aestivus (hay fever or hay asthma). London: Ballière, Tindall and Cox, 1873:77-81.
4. Cooke RA. Studies in specific hypersensitiveness: IX. on the phenomenon of hypersensitization (the clinically lessened sensitiveness of allergy). J Immunol 1922;7:219.
5. Herxheimer H. The late bronchial reaction in induced asthma. Int Arch Allergy Appl Immunol 1952;3:323-8.
6. Pepys T, Turner-Warwick M. Dawson PL. et al. Arthus (Type III) reactions in man: clinical and immunopathological features. Allergology, Excerpta Med Int Cong Ser 1968;162:221-33.
7. Dolovich J, Hargreave FE, Chalmers R, Shier K J, Gauldie J, Bienenstock J. Late cutaneous allergic responses in isolated IgE-dependent reactions. J Allergy Clin Immunol 1973;52:38-46.
8. Solley GO, Gleich GJ, Jordan RE, Schroeter AL. The late phase of the immediate wheal and flare reaction. Its dependence on IgE antibodies. J Clin Invest 1976;58:408-20.
9. Umemoto L, Poothullil J, Dolovich J, Hargreave FE. Factors which influence late cutaneous allergic responses. J Allergy Clin Immunol 1976;58:60-8.
10. Naclerio RM, Proud D, Togias A, Adkinson NF Jr, Meyers DA, Kagey-Sobotka A, et al. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 1985;313:65-70.
11. Bascom R, Wachs M, Naclerio RM, Pipkorn U, Galli SJ, Lichtenstein LM. Basophil influx occurs after nasal antigen challenge: effects of topical corticosteroid pretreatment. J Allergy Clin Immunol 1988;81:580-9.
12. Charlesworth EN, Hood AF, Soter NA, Kagey-Sobotka A, Nerman PS, Lichtenstein LM. Cutaneous late-phase response to allergen: mediator release and inflammatory cell infiltration. J Clin Invest 1989;83:1519-26.
13. Frew AJ, Kay AB. Eosinophils and T-lymphocytes in late-phase allergic reactions. J Allergy Clin Immunol 1990;85:533-9.
14. Miller AR. Delayed allergic reactions in otolaryngology. Northwest Med 1961;60:1190-4.
15. Green GR, Zweiman B, Beerman H, Hidreth EA. Delayed skin reactions to inhalant antigens. J Allergy 1967;40:224-36.
16. Richerson HB, Rajtora DW, Penick GD, et al. Cutaneous and nasal allergic responses in ragweed hay fever: lack of clinical and histopathologic correlations with late phase reactions. J Allergy Clin Immunol 1979;64:67-77.
17. Frew AJ, Kay AB. The pattern of human late-phase skin reactions to extracts of aeroallergens. J Allergy Clin Immunol 1988;81:1117-21.
18. Warner JO, Soothill JF, Price JF, Hey EN. Controlled trial of hyposensitìzation to Dermatophagoides pteronyssinus in children with asthma. Lancet 1978;2:912-7.
19. Cockcroft DW, Ruffin RE, Hargreave FE. Appearance of allergen-induced increases in airway responsiveness only after repeated allergen inhalations in two subjects. Clin Exp Allergy 1989;19:225-7.
20. Atkins P, Green GR, Zweiman B. Histologic studies of human skin test responses to ragweed, compound 48/80, and histamine. J Allergy Clin Immunol 1973;51:263-73.
21. 4) in human skin. J Invest Dermatol 1983;80:115-9.
22. Basran GS, Page CP, Paul W, Morley J. Platelet-activating factor: a possible mediator of the dual response to allergen? Clin Allergy 1984;14:75-9.
23. 4 and PAF-acether in vivo in human skin. J Invest Dermatol 1987;88:675-81.
24. Hargreave FE, Dolovich J, O'Byrne PM, Ramsdale EH, Daniel EE. The origin of airway hyperresponsiveness. J Allergy Clin Immunol 1986;78:825-32.
25. Weiss M, Fisher RH, Kagey-Sobotka A, et al. In vivo response to platelet-derived histamine releasing factor [abstract]. J Allergy Clin Immunol 1988;81:224.
26. Ting S, Dunsky EH, Lavker RM, Zweiman B. Patterns of mast cell alterations and in vivo mediator release in human allergic skin reactions. J Allergy Clin Immunol 1980;66:417-23.
27. Zweiman B, Kornstein M, Atkins P. Immunohistologic studies of late cutaneous allergic reactions [abstract]. J Allergy Clin Immunol 1987;79:169.
28. Shalit M, Schwartz LB, Golzar N, vonAllman C, Valenzano M, Fleekop P, et al. Release of histamine and tryptase in vivo after prolonged cutaneous challenge with allergen in humans. J Immunol 1988;141:821-6.
29. Charlesworth EN, Kagey-Sobotka A, Schleimer RP, Norman PS, Lichtenstein LM. Prednisone inhibits the appearance of inflammatory mediatom and the influx of eosinophils and basophils associated with the cutaneous late-phase response to allergen. J Immunol 1991;146:671-6.
30. Talbot SF, Atkins PC, Goetzl EJ, Zweiman B. Accumulation of leukotriene C, and histamine in human allergic skin reactions. J Clin Invest 1985;76:650-6.
31. Nish WA, Charlesworth EN, Davis TL, Whisman BA, Valtier S, Charlesworth MG, et al. The effect of immunotherapy on the cutaneous late phase response to antigen. J Allergy Clin Immunol 1994;93:484-93.
32. Shalit M, Valone FH, Atkins PC, Ratnoff WD, Goetzel EJ, Zweiman B. Late appearance of phospholipid platelet-activating factor and leukotriene B, in human skin after repeated antigen challenge. J Allergy Clin Immunol 1989;83:691-6.
33. Tamura N, Agrawal DK, Suliaman, Townley RG. Effects of platelet-activating factor on the chemotaxis of normodense eosinophils from normal subjects. Biochem Biophys Res Commun 1987;142:638-44.
34. Chignard M, LeCouedic JP, Vargaftig BB, Benveniste J. Platelet-activating factor secretion from platelets: effect of aggregating agents. Br J Haematol 1980;46:455-64.
35. Chilton FH, Connell TR. 1-0-Alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine: a common source of platelet-activating factor and arachidonate in human polymorphonuclear leukocytes. J Biol Chem 1984;259:12014-9.
36. Henocq E, Vargaftig BB. Accumulation of eosinophils in response to intracutaneous PAF-acether and allergens in man. Lancet 1986;l:1378-9.
37. Bochner BS, Charlesworth EN, Lichtenstein LM, et al. Interleukin-1 is released at sites of human cutaneous allergic reactions. J Allergy Clin Immunol 1990;86:830-9.
38. Schleimer RP, Rutledge BK. Cultured human vascular endothelial cells acquire adhesiveness for neutrophils after stimulation with interleukin 1, endotoxin, and tumor-promoting phorbol diesters. J Immunol 1986;136:649-54.
39. Bevilacqua MP, Pober JS, Mendrick DL, et al. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA 1987;84:9238-42.
40. Subramanian N, Bray MA. Interleukin 1 releases histamine from human basophils and mast cells in vitro. J Immunol 1987;138:271-5.
41. Haak-Frendscho M, Dinarello CA, Kaplan AP. Recombinant human interleukin 1 beta causes histamine release from human basophils. J Allergy Clin Immunol 1988;82:218-23.
42. Thueson DO, Speck LS, Lett-Brown MA, Grant JA. Histamine releasing activity (HRA): II. interaction with basophils and physicochemical characterization. J Immunol 1979;123:633-9.
43. Warner JA, Pienkowski MM, Plaut M, Norman PS, Lichtenstein LM. Identification of histamine releasing factors in the late phase of cutaneous IgE mediated reactions. J Immunol 1986;136:2583-7.
44. Liu M, Proud D, Lichtenstein LM, MacGlashan DW Jr, Schleimer RP, Adkinson NF Jr. Human lung macrophage-derived histaraine releasing activity is due to IgE-dependent factors. J Immunol 1986;136:2588-95.
45. MacDonald SM, Lichtenstein LM, Proud D, et al. Studies on IgE-dependent histamine releasing factors: heterogeneity of IgE. J Immunol 1987;139:506-12.
46. Charlesworth EN, Iliopoulos O, MacDonald SM, et al. Cells and secretagogues involved in the human late-phase response. Int Arch Allergy Appl Immunol 1989;88:50-3.
47. Lee CE, Neuland ME, Teaford HG, et al. lnterleukin-6 is released in the cutaneous response to allergen challenge in atopic individuals. J Allergy Clin Immunol 1992;89:1010-20.
48. Poothullil J, Umemoto L, Dolovich J, Hargreave FE, Day RP. Inhibition by prednisone of the late cutaneous allergic responses induced by antiserum to human IgE. J Allergy Clin Immunol 1976;57:164-7.
49. Pipkorn U, Proud L, Lichtenstein LM, et al. Effect of short term systemic glucocorticoid treatment on human nasal mediator release after antigen challenge. J Clin Invest 1987;80:957-61.
50. Booij-Noord, NN, Orie NGM, deVries K. Immediate and late bronchial obstructive reactions to inhalation of house dust and protective effects of disodium cromoglycate and prednisolone. J Allergy Clin Immunol 1971;48:344.
51. Pipkorn U, Proud D, Lichtenstein LM, et al. Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids. N Engl J Med 1987;316:1506-10.
52. Busse W, Randlev B, Sedgwick J. The effect of azelastine on neutrophil and eosinophil generation of superoxide. J Allergy Clin Immunol 1989;83:400-5.
53. Charlesworth EN, Kagey-Sobotka A, Norman PS, et al. Effect of cetirizine on mast cell-mediator release and cellular traffic during the cutaneous late-phase reaction. J Allergy Clin Immunoi 1989;83:905-12.
54. 1 antagonist (terfenadine) while mediator release is unaffected in vivo and in vitro. Clin Exp Allergy 1993;23:399-405.
55. 1 receptor blockade on the early and late response to cutaneous allergen challenge. J Pharmacol Exp Ther 1992;262:964-70.
56. Leprevost C, Capron M, DeVos C, Tomassini M, Capron A. Inhibition of eosinophil chemotaxis by a new antiallergic compound (cetirizine). Int Arch Allergy Appl Immunol 1988;87:9-13.
57. Alam R, Dejarnatt A, Stafford S, et al. Selective inhibition of the cutaneous late but not immediate allergic response to antigens by misoprostol, a PGE analog. Am Rev Respir Dis 1993;148:1066-70.
58. Fling JA, Ruff ME, Parker MA, Whisman BA, Martin ME, Moss RB, et al. Suppression of the late cutaneous response by immunotherapy. J Allergy Clin Immunol 1989;83:101-9.
59. Charlesworth EN, Nish WA, George T, et al. In vitro eosinophil survival, in vivo histamine release, and skin test reactivity is attenuated following standard high-dose immunotherapy in atopic subjects [abstract], J Allergy Clin Immunol. In press.